Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-23T16:42:44.386Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuropsychiatrie of biologische psychiatrie; een toekomstvisie in historisch perspectief

Published online by Cambridge University Press:  18 September 2015

W.M.A. Verhoeven  and
S. Tuinier
W.M.A. Verhoeven*
Affiliation:
Zenuwarts/A-opleider, Vincent van Gogh Instituut, Venray en Bijzonder Hoogleraar, Erasmus Universiteit, Instituut Psychiatrie, Rotterdam
S. Tuinier
Affiliation:
Psychiater/onderzoekscoördinator, Vincent van Gogh Instituut, Venray
*
zenuwarts, Vincent van Gogh Instituut voor Psychiatrie, Stationsweg 46, 5803 AC Venray
Get access Rights & Permissions [Opens in a new window]

Summary

Neuropsychiatry or Biological Psychiatry There is an urgent need to reconsider the position of psychiatry within the neurosciences because of the exploding knowledge about the relationship between brain and behaviour and the delay in implementation of new findings due to the separation of neurology and psychiatry. Biological psychiatry and psychopharmacology originate from the discovery by chance of psycho-active compounds in the early fifties and have contributed to the scientification of psychiatry. The impact of biological psychiatry for the pathophysiology of psychiatric disorders, however, is limited as a result of its biased orientation on neurotransmitters and receptors. The neuropsychiatric paradigm integrates knowledge from several domains, such as functional neuroanatomy, genetics and endocrinology and opens new vistas for the involvement of neuronal circuits in the initiation and maintenance of behavioural disturbances. In addition, novel and more specific treatment modalities may emerge.

Keywords

Biological psychiatryneuropsychiatrymotivational deficit disorderneuronal circuitsBiologische psychiatrieneurale circuitsneuropsychiatrie
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 11 , Issue 2 , June 1999 , pp. 80 - 84
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1.Trimble, MR. Neuropsychiatry or behavioral neurology. Neurop-sychiat, Neuropsychol Behav Neurol 1993;6;60–9.Google Scholar
2.Godderis, J. Galenos van Pergamon over psychische stoornissen: een bijdrage tot de geschiedenis van de begripsontwikkeling in de psychiatrie. Leuven/Amersfoort: Acco, 1988.Google Scholar
3.Von Bingen, H. Ursachen und Behandlung der Krankheiten. München: Hugo Schulz, 1933.Google Scholar
4.Diethelm, O. Medical Dissertations of psychiatrie Interest: printed before 1750. Basel: Karger, 1971.Google Scholar
5.Neugebauer, R. Treatment of the mentally ill in medieval and early modern England: a reappraisal. J Hist behav Sci 1978;14;158–69.3.0.CO;2-C>CrossRefGoogle Scholar
6.Trevisa, J. On the Properties of Things. Oxford: Clarendon Press, 1998.Google Scholar
7.Manzoni, T. The cerebral ventricles, the animal spirits and the dawn of brain localization of function. Arch Ital Biol 1998;136;103–52.Google ScholarPubMed
8.Hill, D. The bridge between neurology and psychiatry. Lancet 1964-1; 18: 509–14.CrossRefGoogle Scholar
9.Lishman, WA. Neurologists and psychiatrists. In: The bridge between neurology and psychiatry. Reynolds, EH, Trimble, MR, eds. Edinburgh: Churchill Livingstone 1989; 24–37.Google Scholar
10.Benson, DF. Neuropsychiatry and behavioural neurology: past, present, and future. J Neuropsychiat 1996;8;351–7.Google Scholar
11.Verhey, FHM. Acta Neuropsychiatrica; Tijdschrift voor een he-dendaagse neuropsychiatrie. Acta Neuropsychiat 1989;1;3–8.CrossRefGoogle ScholarPubMed
12.Schroeder van der Kolk, JLC. Handboek van de pathologie en therapie der krankzinnigheid. Utrecht: FA Hartsen, 1863.Google Scholar
13.Magnan, V. Leçons cliniques, 2nd edn. Paris: Bataille 1893.Google Scholar
14.Tuinier, S. ‘Gaslighting’. Deopkomst van de psychofarmaca ende anti-psychiatrie. In: Geschiedenis, Psychologie, Mentaliteit. Damen, M, Koedijk, P, Pols, F van der, Teilegen, JW, Veltman, E, eds. Amsterdam, Skript 1982; 77–100.Google Scholar
15.Praag, HM van. ‘Make-believes’ in psychiatry or the perils of progress. New York: Bunner/Mazel, 1993.Google Scholar
16.Praag, HM van. Voorbij de hoofdstroom: over de wetenschappelijke ankerpunten van een psychiatrische loopbaan. Amsterdam: Balans 1998.Google Scholar
17.Grawe, K. Psychotherapieforschung zu Beginn der neunziger Jahre. Psychologische Rundschau 1992;43;132–62.Google Scholar
18.Bertolote, JM, De Girolama, G. Essential Treatment in Psychiatry, Geneve: WHO 1993.Google Scholar
19.Kadera, SW, Lambert, MJ, Andrews, AA. How much therapy is really enough? J Psychother Pract Res 1996;5;132–51.Google Scholar
20.Cummings, JL, Hegarty, A. Neurology, psychiatry and neuropsychiatry. Neurology 1994;44;209–18.CrossRefGoogle ScholarPubMed
21.Laborit, J. Huguenard, P, Alluaume, R. Un nouveau stabilisateur végétatif (le 4560 RF). Press Med 1952;60;206–8.Google Scholar
22.Snyder, SH, Banerjee, SP, Yamamura, HI, Greenberg, D. Drugs, neurotransmitters, and schizophrenia. Science 1974; 184: 1243–53.CrossRefGoogle ScholarPubMed
23.Verhoeven, WMA. Neuropeptides and schizophrenia: a review and critical reappraisal. In: Advances in the Neurobiology of Schizophrenia. Boer, JA den, Westenberg, HGM, Praag, HM van eds. Chichester; John Wiley and Sons, 1995: 303–26.Google Scholar
24.Fekkes, D, Pepplinkhuizen, L. Amino acid studies in transient acute polymorphic psychosis. Amino Acids 1997;12;107–17.CrossRefGoogle Scholar
25.Kahn, RS, Praag, HM van. De rol van Serotonine bij schizofrenie. In: Leerboek schizofrenie. Een neurobiologische benadering. den Boer, J.A. en van den Bosch, R.J. (Eds.). De Tijdstroom Utrecht 1996;143–50.Google Scholar
26.Westenberg, HGM, Den Boer, JA. De neurochemische basis voor psychofarmaca; Over dopamine, Serotonine, cholecystekinine en glutamaat. In: Leerboek schizofrenie. Een neurobiologische benadering. Boer, JA den, Bosch, RJ van den, eds. Utrecht: De Tijdstroom, 1996; 109–27.Google Scholar
27.Kuhn, R. Uber die Behandlung depressiver Zustände mit einem Iminodibenzylderivat (G 22355). Schweiz Med Wochenschr 1957; 35/36: 1135–40.Google Scholar
28.Praag, HM van. Faulty cortisol/serotonin interplay. Psychopatho-logical and biological characterisation of a new, hypothetical depression subtype (SeCA depression). Psychiat Res 1996;65;143–57.CrossRefGoogle Scholar
29.Verhoeven, WMA, Tuinier, S. Neurotransmitters, hormonen en depressies; theorieën over de Pathogenese. In: Handboek Stem-mingsstoornissen. Boer, JA den, Ormel, J, Praag, HM van, Westenberg, HGM, D'haenen, H, eds. Utrecht: De Tijdstroom, 1999; in press.Google Scholar
30.Parnham, MJ, Bruinvels, J. Discoveries in pharmacology, Volume I. Psycho- and Neuro-pharmacology. Amsterdam-New York: Elsevier, 1983.Google Scholar
31.Praag, HM van, Asnis, GM, Kahn, RS, et al.Nosological tunnel vision in biological psychiatry. A plea for a functional psychopathology, Ann N Y Acad Sci 1990;600;501–10.CrossRefGoogle ScholarPubMed
32.Praag, HM van, Leijnse, B. Neubewerting des Syndroms. Skizze einer funktionellen Pathologie. Psychiat neurol Neurochir 1965;8;50–66.Google Scholar
33.Praag, HM van, Asnis, GM, Brown, SL, et al.Beyond serotonin. A multi-aminergic perspective on abnormal behavior. In: Brown, SL, Praag, HM van, eds. The role of serotonin in psychiatry disorders. New York: Brunner/Mazel, 1991: 302–32.Google Scholar
34.Tuinier, S, Verhoeven, WMA. Neurobiologie van agressie en impulsiviteit. Acta Neuropsychiat 1999;11;5–10.CrossRefGoogle Scholar
35.Verhoeven, WMA, Tuinier, S. Symptomatology and Pathophysiology of Psychotic Disorders in Parkinson's Disease. Eur J Psychiat 1995;46;9–37.Google Scholar
36.Stuiver, BT, Sebens, JB, Horst, GJ ter, Korf, J. Huidige inzichten in werkingsmechanismen van psychofarmaca. Pharm Weekbl 1994;129;511–6.Google Scholar
37.Northoff, G. Ansätze zu einer Neuropsychiatrie als Uberbrückung der Trennung von Neurologie und Psychiatrie. Schweiz Arch Neurol Psychiatr 1992;143;27–38.Google Scholar
38.Cummings, JL. Frontal subcortical circuits and human behaviour. Arch Neurol 1993;50;873–80.CrossRefGoogle Scholar
39.Weitzner, MA. Neuropsychiatry and pituitary disease: An overview. Psychother Psychosom 1998;67;125–32.CrossRefGoogle ScholarPubMed
40.Kloet, ER de. Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 1991;12;95–164.Google Scholar
41.Kloet, ER de. Neurobiologie van adaptatiestoornissen. Acta Neuropsychiat 1999;11;11–4.Google Scholar
42.Leshner, AI. Addicton is a brain disease, and it matters. Science 1997;278;45–7.CrossRefGoogle Scholar
43.Saint-Cyr, JA, Taylor, AE, Nicholson, K. Behaviour and the basal ganglia. Adv Neurol 1995;65;1–28.Google ScholarPubMed
44.Verhoeven, WMA, Tuinier, S, Berg, YWMM van den, Coppus, , et al.Stress and self-injurious behaviour; hormonal and serotonergic parameters in mentally retarded subjects. Pharmacopsychiat 1999;32;13–20.CrossRefGoogle ScholarPubMed
45.Verhoeven, WMA, Tuinier, S. Neuropsychiatriche diagnostiek. In: Verhoeven, WMA, Tuinier, S, Curfs, LMG, eds. Diagnostiek en behandeling van gedragsproblemen bij verstandelijk gehandicapten. Cure & Care Development, 1999; in press.Google Scholar
46.Marin, RS. Apathy: A neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991;3;243–54.Google Scholar
47.Marin, RS, Fogel, BS, Hawkins, J, Duffey, J, Krupp, B. Apathy: A treatable syndrome. J Neuropsychiat clin Neurosci 1995; 7: 23–30.Google Scholar
48.Müller, U, Von Cramon, Y. The therapeutic potential of bromocriptine in neuropsychological rehabilitation of patiens with acquired brain damage. Prog Neuropsychopharmacol Biol Psychiat 1994;18;1103–20.CrossRefGoogle Scholar
49.Cummings, JL. Motility, behaviour and the brain. J psychosom Res 1998;44;643–44.Google ScholarPubMed
50.Sandman, CA, Hetrick, W, Taylor, DV, Chicz-DeMet, A. Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers. Am J ment Retard 1997;102;182–99.2.0.CO;2>CrossRefGoogle ScholarPubMed
51.Tuinier, S, Verhoeven, WMA. Dimensional classification and behavioral pharmacology of personality disorders; a review and hypothesis. Eur Neuropsychopharmacol 1995;5;135–46.CrossRefGoogle ScholarPubMed
52.Kandel, ER. A new intellectual framework for psychiatry. Am J Psychiatry 1998;155;457–69.CrossRefGoogle ScholarPubMed
53.Coffey, CD, Cummings, JL, Duffy, JD, et al.Assessment of treatment outcomes in neuropsychiatry: A report from the committee on research of the American Neuropsychiatric Association. J Neuropsychiatr clin Neurosci 1995;7;287–9.Google Scholar
54.Cummings, JL, Coffey, CE, Duffy, JD, et al.The clinician-scientist in neuropsychiatry: A position statement from the committee on research of the American Neuropsychiatric Association. J Neuropsychiat clin Neurosci 1998;10;1–9.CrossRefGoogle Scholar
55.Ministerie van Volksgezondheid, Welzijn en Sport. Beleidsvisie Geestelijke Gezondheidszorg 1999. 's-Gravenhage: Ministerie van VWS, 1998.Google Scholar
56.Verhoeven, WMA, Goessens, LFM, Berg, YWMM van den, Tuinier, S. Integratie van opleiding en onderzoek in de opleiding tot psychiater. Acta Neuropsychiat 1999;11;18–23.CrossRefGoogle ScholarPubMed